Dr. Michael Rome joined Foresite Capital in 2016 and leads the therapeutics investing practice. Michael previously served on the boards of XinThera (acquired by Gilead Sciences), Affinivax (observer, acquired by GSK), Turning Point Therapeutics (observer, acquired by BMS), Pharvaris (Nasdaq: PHVS), Nurix Therapeutics (Nasdaq: NRIX, observer), and Alumis where he led the acquisition of Fronthera Biopharma. He currently serves as a board director at Kinnate Biopharma (Nasdaq: KNTE), Remix Therapeutics, Theseus Pharmaceuticals (Nasdaq: THRX) and Avenzo Therapeutics. Michael served as Vice President for Foresite Development Corporation I & II. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering therapeutics companies. He earned a BS in Molecular, Cell, and Developmental Biology from UCLA and obtained his PhD in Biochemistry at Caltech as an NSF Fellow.
- Head of the therapeutics investment team at Foresite Capital, a multidisciplinary team comprising individuals with expertise in biopharma, finance, and academic science.
- Experience leading company formation, mergers and acquisitions, and private/public company structured financings.
- Board director and officer at multiple publicly traded biotechnology companies.